Wisevoter
U.S.

Fractyl Reports $31.5 Million Cash for Quarter

The company says its cash will fund operations through planned regulatory filings and early 2027 data for its weight-maintenance therapy Revita.

Updated on Nov. 13, 2026 in Weight Loss

Bold vector editorial illustration of a coiled endoscope tube and catheter beside plain amber glass vials, set in generous negative space.
Fractyl Therapeutics reported $31.5 million in cash on September 30, 2026, saying its funds will carry the company through a planned De Novo application for its weight-maintenance device Revita. AI Illustration. Upload story photo >

Live Poll

Would you consider an endoscopic procedure to keep weight off after stopping GLP-1 medication?

Fractyl had $31.5 million in cash and cash equivalents on September 30, 2026. The company plans to submit a De Novo application for Revita, an investigational endoscopic therapy intended to help people maintain weight loss after stopping GLP-1 treatment.

Why it matters

Revita is aimed at a common problem with GLP-1 drugs, where weight often returns after treatment stops. Fractyl's runway and additional capital needs will determine whether the therapy can reach the U.S. market.

Six-month results showed participants receiving Revita retained about 80% of the weight they had lost on tirzepatide, meeting the study's co-primary endpoint. Fractyl's disclosure does not yet say how much further capital will be needed to bring the therapy to market.

The players

Fractyl

Fractyl is a company developing endoscopic therapies for metabolic diseases, including Revita for weight-maintenance after GLP-1 treatment.

The details

Revita is delivered as an endoscopic therapy and is being studied in participants who first lost weight on tirzepatide. Fractyl expects its current cash to fund operations through a De Novo application in late Q4 2026 and topline 12-month data from the REMAIN-1 Pivotal Cohort in Q1 2027.

Timeline

  1. September 30, 2026: Fractyl reports $31.5 million in cash and cash equivalents.

  2. Late Q4 2026: Fractyl plans to submit its De Novo marketing application for Revita.

  3. Q1 2027: Topline 12-month data from the REMAIN-1 Pivotal Cohort is expected.

  4. End of Q2 2027: Quarterly operating cash spending is projected to fall to about $8 million.

Big Picture

Weight regain after stopping GLP-1 drugs such as tirzepatide has become a central concern in obesity care, and Revita is positioned as a non-drug follow-on to that treatment. Fractyl's regulatory timeline will test whether an endoscopic option can address that gap.

If Revita is approved, people who stop GLP-1 medication could have an endoscopic option aimed at keeping weight off. The therapy is still investigational, so no treatment is available to patients at this stage.

The takeaway

Weight maintenance after GLP-1 treatment is a distinct challenge from weight loss itself, and watching Fractyl's regulatory milestones will show whether new options reach patients. Readers considering these medications should discuss long-term weight plans with a clinician.

What happens next

Fractyl plans to submit its De Novo application for Revita in late Q4 2026, followed by topline 12-month REMAIN-1 data in Q1 2027.

Further reading

Explore more coverage in Weight Loss for context on GLP-1 treatments and weight maintenance.

Source note: This article includes information reported by TokenPost.

Live Poll

Would you consider an endoscopic procedure to keep weight off after stopping GLP-1 medication?